Standard Article

You have free access to this content

Down Syndrome

  1. Angela J Villar,
  2. Charles J Epstein

Published Online: 27 JAN 2006

DOI: 10.1038/npg.els.0005711

eLS

eLS

How to Cite

Villar, A. J. and Epstein, C. J. 2006. Down Syndrome. eLS. .

Author Information

  1. University of California, San Francisco, California, USA

Publication History

  1. Published Online: 27 JAN 2006

This is not the most recent version of the article. View current version (17 OCT 2011)

References

  1. References
  2. Further Reading
  • Baird PA and Sadovnick AD (1987) Life expectancy in Down syndrome. Journal of Pediatrics 110: 849.
  • Groner Y (1995) Transgenic models for chromosome 21 gene dosage effects. In: Epstein CJ, Hassold T, Lott IT, Nadel L and Patterson D (eds.) Etiology and Pathogenesis of Down Syndrome, p. 193. New York, NY: Wiley-Liss.
  • Hanson MJ (1987) Early intervention for children with Down syndrome. In: Pueschel SM, Tingey C, Rynders JE, Crocker AC and Crutcher DM (eds.) New Perspectives on Down Syndrome, p. 149. Baltimore, MD: PH Brooks.
  • Hattori M, Fujiyama A, Taylor TD, et al. (2000) The DNA sequence of human chromosome 21. Nature 405: 311.
  • Lamb NE, Feingold E, Savage A, et al. (1997) Characterization of susceptible chiasma configurations that increase the risk for maternal nondisjunction of chromosome 21. Human Molecular Genetics 6: 1391.
  • Murphy M, Insoft RM, Pike-Nobile L and Epstein CJ (1995) A hypothesis to explain the immune defects in Down syndrome. In: Epstein CJ, Hassold T, Lott IT, Nadel L and Patterson D (eds.) Etiology and Pathogenesis of Down Syndrome, p. 147. New York, NY: Wiley-Liss.
  • Reeves RH, Irving NG, Moran T, et al. (1995) A mouse model for Down syndrome exhibits learning and behavioral and deficit. Nature Genetics 11: 177.
  • Rumble B, Retallack R, Hilbich C, et al. (1989) Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. New England Journal of Medicine 320: 1446.
  • Sago H, Carlson EJ, Smith DJ, et al. (2000) Genetic dissection of the region associated with behavioral abnormalities in mouse models for down syndrome. Pediatric Research 48: 606613.
  • Zipursky A, Peeters M and Poon A (1987) Megakaryoblastic leukemia and Down's syndrome – a review. In: McCoy EE and Epstein CJ (eds.) The Oncology and Immunology of Down Syndrome, p. 33. New York, NY: Liss.

Further Reading

  1. References
  2. Further Reading
  • Dellarco VL, Voytek PE and Hollaender A (eds.) (1985) Aneuploidy: Etiology and Mechanisms. New York, NY: Plenum.
  • Epstein CJ (1986) The Consequences of Chromosome Imbalance. Principals, Mechanisms, and Models. New York, NY: Cambridge University Press.
  • Epstein CJ (ed.) (1991) The Morphogenesis of Down Syndrome. New York, NY: Wiley-Liss.
  • Epstein CJ (ed.) (1993) The Phenotype Mapping of Down Syndrome and Other Aneuploid Conditions. New York, NY: Wiley-Liss.
  • Epstein CJ (2001) Down syndrome (trisomy 21). In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds.) The Metabolic Basis of Inherited Disease, 8th edn. pp. 11231256, New York, NY: McGraw-Hill.
  • Epstein CJ, Hassold T, Lott IT, Nadel L and Patterson D (eds.) (1995) Etiology and Pathogenesis of Down Syndrome. New York, NY: Wiley-Liss.
  • McCoy EE and Epstein CJ (eds.) (1987) The Oncology and Immunology of Down Syndrome. New York, NY: Liss.
  • Nadel L and Epstein CJ (eds.) (1992) Downs Syndrome and Alzheimer Disease. New York, NY: Wiley-Liss.
  • Pueschel SM, Sassaman EA, Scola PS, et al. (1982) Biomedical aspects in Down syndrome. In: Pueschel SM and Rynders JE (eds.) Down Syndrome. Advances in Biomedicine and the Behavioral Sciences, p. 169. Cambridge, MA: Ware.
  • Smith GF and Berg JM (1976) Down's Anomaly. Edinburgh, UK: Churchill Livingstone.